BridgeBio Pharma (NASDAQ:BBIO) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

BridgeBio Pharma (NASDAQ:BBIO) issued its quarterly earnings results on Thursday. The company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.04, Yahoo Finance reports. The business had revenue of $26.74 million for the quarter.

Shares of BBIO stock traded up $2.64 on Friday, hitting $27.06. 290,200 shares of the stock traded hands, compared to its average volume of 279,343. BridgeBio Pharma has a 52 week low of $17.61 and a 52 week high of $32.94. The business has a 50 day moving average price of $20.88.

Several research analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set a “buy” rating and a $38.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set an “overweight” rating and a $38.00 price target on the stock. Raymond James assumed coverage on shares of BridgeBio Pharma in a research note on Friday, July 26th. They set an “outperform” rating and a $36.00 price target on the stock. BMO Capital Markets assumed coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $49.00 price target on the stock. Finally, Svb Leerink assumed coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $34.00 price target on the stock. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $40.13.

About BridgeBio Pharma

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Featured Article: Diversification Important in Investing

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply